The LWCN Strategy Board maintains strategic oversight of Lymphoedema Wales Clinical Network (LWCN) and considers, scrutinises and agrees recommendations made by the LWCN Programme Board providing assurance and endorsement to the All Wales NHS Chief Executives Forum.

The LWCN Strategy Board provides the source of composite advice to Welsh Government, Chief Executive Officers and Health Boards as required and informs Welsh Government of the progress towards benefit realisation of the programme.

The Board meets bi-annually and is chaired by a Chief Executive of one of the seven Welsh Health Boards.

Strategy Board Representatives

The current chair of the LWCN Strategy Board is Nicola Prygodzicz, Chief Executive, Aneurin Bevan University Health Board and includes the following representation:

  • Clinical Director, LWCN
  • National Lymphoedema Education & Research Lead, LWCN
  • Programme Management Office Representation, LWCN
  • Chair LWCN Programme Board
  • Health of Older People’s Health & Chronic Conditions Management, Welsh Government
  • Director of Therapies and Health Sciences, SBUHB
  • Director of Improvement & Innovation, CTMUHB
  • Director Clinical Strategy, PTHB
  • Director of Transformation, BCUHB
  • Director of Nursing, CVUHB
  • Director Primary and Community Care, ABUHB
  • Associate Medical Director Transformation and Value Based Health Care, HDUHB
  • Chief Pharmacy, Velindre
  • Deputy Director of Finance, Velindre
  • Director of Digital Strategy, Digital Health and Care Wales
  • Academic Representative
  • Health Care Inspectorate Wales Representative
  • Patient Representatives
  • Assistant Director Finance, Finance Delivery Unit